tetano
Editor, Senior Moderator
Front Public Health
. 2022 Mar 16;10:816848.
doi: 10.3389/fpubh.2022.816848. eCollection 2022.
The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
Marie Kroemer[SUP] 1 2 [/SUP], Laura Boullerot[SUP] 1 3 [/SUP], Mélanie Ramseyer[SUP] 3 [/SUP], Laurie Spehner[SUP] 1 4 [/SUP], Christophe Barisien[SUP] 5 [/SUP], Eleonore Gravelin[SUP] 3 [/SUP], Adeline Renaudin[SUP] 3 [/SUP], Fabrice Cognasse[SUP] 6 7 [/SUP], Pierre Gallian[SUP] 8 9 [/SUP], Olivier Hermine[SUP] 10 11 [/SUP], Karine Lacombe[SUP] 12 13 [/SUP], Pierre Tiberghien[SUP] 1 8 [/SUP], Olivier Adotévi[SUP] 1 3 14 [/SUP]
Affiliations
Abstract
Convalescent plasma therapy has been described as an attractive approach to treat critically ill patients with COVID-19 (Coronavirus disease 2019). The selection of convalescent plasma donors (CPD) is commonly based on neutralizing antibody titer. A better understanding of the quality of immune responses following COVID-19 will enable the optimization of convalescent donors' selection in convalescent plasma programs. The involvement of SARS-CoV-2 specific T cells in the induction and persistence of high affinity anti-SARS-CoV-2 neutralizing antibody is still poorly investigated. In this study, 115 CPD who presented SARS-CoV-2 and who were eligible for plasma donation were included. Comprehensive analysis of T cells together with humoral responses were performed in regards of sex, age and blood group type. High frequency of T cell responses against SARS-CoV-2 related protein such as spike glycoprotein (80.0%), nucleocapsid (NCAP) (70.4%) and membrane protein (VME1) (74.8%) were detected in CPD by ex vivo IFN-γ and TNF-α ELISpot assays. Among CPD responders, most exhibited poly-specific T cell responses (75%) defined by the ability to mount responses against at least two SARS-CoV-2 antigens. We found a positive correlation between the magnitude and the poly-specificity of anti-SARS-CoV-2 T cell responses in CPD. Notably, both the magnitude and poly-specificity of SARS-CoV-2 T cell responses were highly correlated with neutralizing antibody titer in CPD. The present study highlights that the poly-specificity and strength of SARS-CoV-2 specific T cell responses predicts neutralizing antibody titer following COVID-19. These observations show the interest to combine T cell assays and antibody titer for the selection of CPD and to a latter extend to assess COVID-19 vaccine efficacy in at-risk patients.
Keywords: COVID-19; COVID-19 serotherapy; T cell; neutralizing antibodies; t-lymphocyte.
. 2022 Mar 16;10:816848.
doi: 10.3389/fpubh.2022.816848. eCollection 2022.
The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
Marie Kroemer[SUP] 1 2 [/SUP], Laura Boullerot[SUP] 1 3 [/SUP], Mélanie Ramseyer[SUP] 3 [/SUP], Laurie Spehner[SUP] 1 4 [/SUP], Christophe Barisien[SUP] 5 [/SUP], Eleonore Gravelin[SUP] 3 [/SUP], Adeline Renaudin[SUP] 3 [/SUP], Fabrice Cognasse[SUP] 6 7 [/SUP], Pierre Gallian[SUP] 8 9 [/SUP], Olivier Hermine[SUP] 10 11 [/SUP], Karine Lacombe[SUP] 12 13 [/SUP], Pierre Tiberghien[SUP] 1 8 [/SUP], Olivier Adotévi[SUP] 1 3 14 [/SUP]
Affiliations
- PMID: 35372242
- PMCID: PMC8965758
- DOI: 10.3389/fpubh.2022.816848
Abstract
Convalescent plasma therapy has been described as an attractive approach to treat critically ill patients with COVID-19 (Coronavirus disease 2019). The selection of convalescent plasma donors (CPD) is commonly based on neutralizing antibody titer. A better understanding of the quality of immune responses following COVID-19 will enable the optimization of convalescent donors' selection in convalescent plasma programs. The involvement of SARS-CoV-2 specific T cells in the induction and persistence of high affinity anti-SARS-CoV-2 neutralizing antibody is still poorly investigated. In this study, 115 CPD who presented SARS-CoV-2 and who were eligible for plasma donation were included. Comprehensive analysis of T cells together with humoral responses were performed in regards of sex, age and blood group type. High frequency of T cell responses against SARS-CoV-2 related protein such as spike glycoprotein (80.0%), nucleocapsid (NCAP) (70.4%) and membrane protein (VME1) (74.8%) were detected in CPD by ex vivo IFN-γ and TNF-α ELISpot assays. Among CPD responders, most exhibited poly-specific T cell responses (75%) defined by the ability to mount responses against at least two SARS-CoV-2 antigens. We found a positive correlation between the magnitude and the poly-specificity of anti-SARS-CoV-2 T cell responses in CPD. Notably, both the magnitude and poly-specificity of SARS-CoV-2 T cell responses were highly correlated with neutralizing antibody titer in CPD. The present study highlights that the poly-specificity and strength of SARS-CoV-2 specific T cell responses predicts neutralizing antibody titer following COVID-19. These observations show the interest to combine T cell assays and antibody titer for the selection of CPD and to a latter extend to assess COVID-19 vaccine efficacy in at-risk patients.
Keywords: COVID-19; COVID-19 serotherapy; T cell; neutralizing antibodies; t-lymphocyte.